involvement (69%), and without perineural invasion (96%) or lymphovascular invasion (94%). Most tumors were primarily resected (81%), and most adjuvant therapy was used in higher T-class cases (see supplemental eTable 2) . Of patients undergoing excision, 15
Search Results
Evaluation of AJCC and an Alternative Tumor Classification System for Primary Vulvar Squamous Cell Carcinoma
Sarah T. Le, Pritesh S. Karia, Beverley J. Vollenhoven, Robert J. Besaw, Colleen M. Feltmate, and Chrysalyne D. Schmults
A Routine Laboratory Data–Based Model for Predicting Recurrence After Curative Resection of Stage II Colorectal Cancer
Zhong Ye, Chun Wang, Limin Guo, Juan P. Palazzo, Zhixing Han, Yinzhi Lai, Jing Jiang, James A. Posey, Atrayee Basu Mallick, Bingshan Li, Li Jiang, and Hushan Yang
only a small portion of patients with stage II CRC, but is unnecessary in up to 70% of patients who might be cured by surgery alone. 5 , 6 According to a recent Cochrane systematic review, adjuvant therapy improves overall survival (OS) in <10% of
Sequential Versus Concurrent Chemoradiation Therapy by Surgical Margin Status in Resected Non–Small Cell Lung Cancer
Vivek Verma, Amy C. Moreno, Waqar Haque, Penny Fang, and Steven H. Lin
therapy referred to starting chemotherapy and RT within 14 days of each other, with the remainder designated as sequential. 25 , 26 Patients with an interval of >6 months from surgery to adjuvant therapy, or between adjuvant RT and chemotherapy, were
Long-Term Outcomes of dMMR/MSI-H Rectal Cancer Treated With Anti–PD-1–Based Immunotherapy as Curative-Intent Treatment
Jie-Hai Yu, Le-En Liao, Bin-Yi Xiao, Xuan Zhang, Ai-Wen Wu, Yong Cheng, Jing-Hua Tang, Wu Jiang, Ling-Heng Kong, Kai Han, Wei-Jian Mei, Zhi-Gang Hong, Wan-Jun Yang, Dan-Dan Li, Zhi-Zhong Pan, Yun-Feng Li, Xiao-Shi Zhang, and Pei-Rong Ding
inhibitors in non-small cell lung cancer . Nat Commun 2021 ; 12 : 5045 . 32. Eljilany I , Noor A , Paravathaneni M , Granulomatous and sarcoid-like immune-related adverse events following CTLA4 and PD1 blockade adjuvant therapy of melanoma: a
Impact of Nonadherence to NCCN Adjuvant Radiotherapy Initiation Guidelines in Head and Neck Squamous Cell Carcinoma in an Underserved Urban Population
Anusha Ponduri, David Z. Liao, Nicolas F. Schlecht, Gregory Rosenblatt, Michael B. Prystowsky, Rafi Kabarriti, Madhur Garg, Thomas J. Ow, Bradley A. Schiff, Richard V. Smith, and Vikas Mehta
intuitively would delay the initiation of adjuvant therapy. Patients with underweight BMI may be sarcopenic, which leads to increased postoperative complications. 26 Being underweight at diagnosis has been shown as an independent, adverse prognostic factor in
Uterine Sarcoma, Version 1.2016
Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, Kathleen R. Cho, Christina Chu, David Cohn, Marta Ann Crispens, Don S. Dizon, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Suzanne George, Ernest Han, Susan Higgins, Warner K. Huh, John R. Lurain III, Andrea Mariani, David Mutch, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Todd Tillmanns, Fidel A. Valea, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone
primary surgery, with adjuvant therapy as indicated. For patients not suitable to receive primary surgery, primary treatment recommendations include systemic therapy and/or pelvic radiation therapy (RT) with or without brachytherapy. Systemic therapy is an
Principles of Treatment for Borderline, Micropapillary Serous, and Low-Grade Ovarian Cancer
Kari E. Hacker, Shitanshu Uppal, and Carolyn Johnston
patients with pathology upgraded to carcinoma were included in analyses. 53 Finally, some gynecologic oncologists recommend completion of surgery after childbearing, because most recurrences are in the contralateral ovary. 56 Adjuvant therapy is
Advanced Hormone-Sensitive Breast Cancer: Overcoming Resistance
Ingrid A. Mayer
by progressive disease within 6 months of starting treatment with endocrine therapy in the metastatic setting, or the development of metastatic recurrence during or shortly after completing adjuvant therapy. Secondary (acquired) resistance is
Kidney Cancer: Current and Novel Treatment Options
Eric Jonasch
not support the use of adjuvant therapy for RCC in 2015. With the advent of various antiangiogenic agents and mTOR inhibitors, investigators have moved past the cytokine therapy era, he noted. In the upcoming years, Dr. Jonasch predicted, the next wave
Disparities in Adjuvant Endocrine Therapy
Elizabeth J. Cathcart-Rake and Kathryn J. Ruddy
: Lessons From Medicare Part D,” in this issue of JNCCN (page 1509 ) adds to the current literature on cancer care disparities in that it reveals how state-level variability in Medicare Part D benefits influence adjuvant therapy prescriptions